Slide 1: GNI Group Ltd. Q2 FY2021 Financial Results
GNI Group Ltd. Q2 FY2021 Financial Results Corporate Presentation August 18, 2021 We Bring New Hope to Patients Securities Code: 2160
Slide 2: Forward-looking Statements
We Bring New Hope to Patients Forward-looking Statements This presentation contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (GNI Group). Any statements contained herein that pertain to future operating performance and that are not historic facts are for
Slide 3: FY2021 – Q2 Highlights
We Bring New Hope to Patients FY2021 – Q2 Highlights Revenue increased 47.6% year on year, achieved an increase in all profits - Revenue trend of Etuary® is steady - Acceleration of revenue and profitability recovery in our Medical Device Segment (Biomaterials) - Through the acquisition of Reveal
Slide 4: FY2021-Q2 Consolidated Financial Results Comparison (YoY)
We Bring New Hope to Patients FY2021-Q2 Consolidated Financial Results Comparison (YoY) Million yen : Amounts of less than one million yen are rounded down FY2020 FY2021 Revenue & Gross Profit Statements of Income Jan.-June Jan.-June Change Due to continuous strong sales of Etuary® in China in which
Slide 5: Forecasts for FY2021
We Bring New Hope to Patients Forecasts for FY2021 Revised Forecasts of Consolidated Financial Results for FY2021 Profit Operating Profit for the attributable to Basic earnings Revenue Profit before Profit year owners of the per share tax parent Million yen Million yen Million yen Million yen Millio
Slide 6: Development: Pipeline Update
We Bring New Hope to Patients Development : Pipeline Update Product - Indication Origin Phase I Phase II Phase III Latest Status Etuary® (China) - Connective Tissue Disease Associated Proprietary Dual Phase III clinical trials ongoing. Proceeding smoothly Interstitial Lung Disease (CTD-ILD) - Radiat
Slide 7: Topics
We Bring New Hope to Patients Topics Received approval for F351 Phase III clinical trial in China and preparing for the start - Without an effective and approved therapy for liver fibrosis anywhere in the world, the development of F351 is a significant milestone for a disease which affects million
Slide 8: Investing in Both Healthcare and Related Businesses
We Bring New Hope to Patients Investing in Both Healthcare and Related Businesses Profitable New Business 1. Reveal - CellCarta, a global precision medical services company, acquired GNI Group’s ownership of Reveal (6% in 2019 for 111 million yen) - As part of this transaction, GNI Group exchanged i
Slide 9: Future Direction
We Bring New Hope to Patients Future Direction 1. Target profitable growth while continuously investing into drug discovery globally 2. Realize the value of core assets of GNI Group – Beijing Continent Pharmaceutical Co., Cullgen Inc., Berkeley Advanced Biomaterials LLC, and Shanghai Genomics, Inc.
Slide 10: Contact Information
We Bring New Hope to Patients Contact Information infojapan@gnipharma.com © 2021 GNI Group Ltd. All rights reserved 10